Teva Pharmaceutical shares rise 2.18% premarket after Q2 profit beats estimates.

miércoles, 30 de julio de 2025, 7:34 am ET1 min de lectura
TEVA--
Teva Pharmaceutical Industries Limited rose 2.18% in premarket trading. The company reported a Q2 profit that exceeded estimates, driven by gains in branded drugs. Additionally, Teva's innovative portfolio has fueled its 10th consecutive quarter of growth, indicating strong performance and potential for future success.

Teva Pharmaceutical shares rise 2.18% premarket after Q2 profit beats estimates.

Comentarios



Add a public comment...
Sin comentarios

Aún no hay comentarios